Thalidomide in actinic prurigo

Lovell, C. R.; Hawk, J.L.M.; Calnan, C. D.; Magnus, I.A.

doi:10.1111/j.1365-2133.1983.tb04601.x

Cited by 83 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it remains an experimental treatment for a variety of inflammatory skin disorders. 18 Among those reported included actinic prurigo, 19,20 orogenital ulcerations, [21][22][23] Weber-Christian disease, 24 graft-vs-host disease, [25][26][27][28] and chronic cutaneous lupus erythematosus (CCLE). 29,30 Many European studies have documented that thalidomide is an effective treatment for various inflammatory dermatoses, such as cutaneous lupus erythematosus (CLE), that are unresponsive to standard therapy.…”

Section: Discussionmentioning

confidence: 99%

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Duong¹,

Spigel²,

Moxley³

et al. 1999

Arch Dermatol

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Duong¹,

Spigel²,

Moxley³

et al. 1999

Arch Dermatol

View full text Add to dashboard Cite

“…Subjects remained in a fasted state for a further 4 hr postdosing. Blood samples, for drug analysis, were taken at the following times: predose (up to 30 min prior to dosing); every half-hour for 3 hr; then at 4,5,6,8,10,12,16,20,24, and 48 hr postdose. To prevent any spontaneous hydrolysis of the drug, blood samples were placed immediately in ice and all subsequent processing was carried out at 4°C.…”

Section: Subjects and Study Outlinementioning

confidence: 99%

Pharmacokinetics and Hemodynamic Effects of Single Oral Doses of Thalidomide in Asymptomatic Human Immunodeficiency Virus-Infected Subjects

Noormohamed

Youle²,

Higgs³

et al. 1999

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Thalidomide (alpha-N-phthalimidoglutarimide), a potent inhibitor of tumor necrosis factor alpha (TNF-alpha), is proving to be a promising drug in the treatment of a number of inflammatory, autoimmune, and HIV-associated disorders. The pharmacokinetics and hemodynamic effects of two single oral doses of thalidomide (100 and 200 mg) were investigated, using a randomized, two-period crossover design, in a group of asymptomatic, male HIV-seropositive subjects. Thalidomide pharmacokinetics were linear at the doses studied, and were best described by a one-compartment model with first-order absorption and elimination processes. The drug was rapidly absorbed, with a mean absorption half-life of 0.95 hr (range, 0.16-2.49 hr) and 1.19 hr (range, 0.33-3.53 hr) after 100- and 200-mg doses, respectively. The corresponding mean Cmax values were 1.15+/-0.24 microg/ml (100 mg) and 1.92+/-0.47 microg/ml (200 mg; p<0.001), which were achieved (Tmax) at 2.5+/-1.5 h and 3.3+/-1.4 hr, respectively. Plasma concentrations of thalidomide declined thereafter, in a log-linear manner, with elimination half-lives of 4.6+/-1.2 hr (100 mg) and 5.3+/-2.2 hr (200 mg). The apparent volumes of distribution (Vdss/F) were 69.9+/-15.6 liters (100 mg) and 82.7+/-34.9 liters (200 mg) while total body clearances (Cl/F) were 10.4+/-2.1 and 10.8+/-1.7 liters/hr, respectively. Significant dose-dependent decreases in supine systolic and diastolic blood pressures were seen for up to 2 hr postdosing; somnolence, headache, dizziness, and confusion were also reported more frequently at the higher dose of thalidomide.

show abstract

“…However, pruritus is the predominant symptom which is usually noted at early phases of the disease [19]. AP is often refractory to therapy, although topical, intralesional or systemic steroids [6], psoralen plus ultraviolet A [20], azathioprine [2], cyclosporine [8]and thalidomide [9]have been used with variable results. In our patients, oral intake of PTX induced a significant improvement in overall assessment.…”

Section: Commentmentioning

confidence: 99%

“…Treatment of AP patients has relied on topical corticosteroids [6], tetracycline [7], cyclosporine [8]and thalidomide [9]. Thalidomide inhibits the synthesis of the proinflammatory cytokine tumor necrosis factor α (TNF-α) and may act as an immunomodulating agent on T-cell subsets [10, 11].…”

Section: Introductionmentioning

confidence: 99%

Pentoxifylline in the Treatment of Actinic Prurigo

Torres-Álvarez¹,

Castanedo-Cázares²,

Moncada³

2004

Dermatology

View full text Add to dashboard Cite

Background: Actinic prurigo (AP) is a chronic familial photodermatosis usually seen in Latin-American Mestizo and Indian populations. It frequently begins in childhood and is more prevalent in females. The pathogenesis of AP has not been clearly elucidated, but previous studies have suggested an immune-mediated condition. Many drugs have been employed to treat AP patients with variable success. Objective: To assess the clinical efficacy of pentoxifylline (PTX) in the treatment of AP patients by measuring its effects on lesions and pruritus. Methods: 10 patients with severe AP were included to receive PTX in a 6-month open-label uncontrolled study. Results: Clinical improvement of lesions was evident in all patients. Relief in pruritus was evident after 1 month of treatment and was maintained while receiving PTX. Five patients were followed up for 2 years, 2 obtained complete remission, and 3 had an important reduction in the use of corticosteroids. Conclusion: PTX was useful in the treatment of our actinic prurigo patients. It may induce a complete or partial remission of lesions and allow a decrease in the use of topical corticosteroids.

show abstract

Thalidomide in actinic prurigo

Cited by 83 publications

References 13 publications

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus

Pharmacokinetics and Hemodynamic Effects of Single Oral Doses of Thalidomide in Asymptomatic Human Immunodeficiency Virus-Infected Subjects

Pentoxifylline in the Treatment of Actinic Prurigo

Contact Info

Product

Resources

About